159 related articles for article (PubMed ID: 10760430)
61. A phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy of unrespectable head and neck cancer.
Machtay M; Aviles V; Kligerman MM; Treat J; Weinstein GS; Weber RS; Mirza N; Chalian AA; Rosenthal DI
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):311-5. PubMed ID: 10760424
[TBL] [Abstract][Full Text] [Related]
62. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Abe M
Jpn J Cancer Res; 1996 Jan; 87(1):98-104. PubMed ID: 8609056
[TBL] [Abstract][Full Text] [Related]
63. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
[TBL] [Abstract][Full Text] [Related]
64. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
65. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
66. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study.
Vokes EE; Haraf DJ; Masters GA; Hoffman PC; Drinkard LC; Ferguson M; Olak J; Watson S; Golomb HM
Semin Oncol; 1996 Apr; 23(2 Suppl 5):48-52. PubMed ID: 8610237
[TBL] [Abstract][Full Text] [Related]
67. Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude mice.
Cardinale RM; Dillehay LE; Williams JA; Tabassi K; Brem H; Lee DJ
Radiat Oncol Investig; 1998; 6(2):63-70. PubMed ID: 9572682
[TBL] [Abstract][Full Text] [Related]
68. Radiation sensitization with redox modulators: a promising approach.
Rosenberg A; Knox S
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):343-54. PubMed ID: 16414370
[TBL] [Abstract][Full Text] [Related]
69. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
70. Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts.
Huxham LA; Kyle AH; Baker JH; McNicol KL; Minchinton AI
Radiother Oncol; 2006 Feb; 78(2):138-45. PubMed ID: 16455148
[TBL] [Abstract][Full Text] [Related]
71. Impact of nicotinamide on human tumour hypoxic fraction measured using the comet assay.
McLaren DB; Pickles T; Thomson T; Olive PL
Radiother Oncol; 1997 Nov; 45(2):175-82. PubMed ID: 9424009
[TBL] [Abstract][Full Text] [Related]
72. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
[TBL] [Abstract][Full Text] [Related]
73. [Evaluation of the toxicity of tirapazamine plus cisplatin in a mouse tumor model].
Adam M; Ottenjann S; Künzel G; Busch R; Erhardt W; Nieder C; Molls M
Strahlenther Onkol; 2006 Apr; 182(4):231-9. PubMed ID: 16622625
[TBL] [Abstract][Full Text] [Related]
74. Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study.
Smith HO; Jiang CS; Weiss GR; Hallum AV; Liu PY; Robinson WR; Cheng PC; Scudder SA; Markman M; Alberts DS
Int J Gynecol Cancer; 2006; 16(1):298-305. PubMed ID: 16445649
[TBL] [Abstract][Full Text] [Related]
75. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
Langer CJ; Duffy K; Horwitz EM; Litwin S; Rosvold E; Schol J; Keenan E; Nicolaou N; Friedman CD; Ridge JA
Cancer Invest; 2006 Mar; 24(2):164-73. PubMed ID: 16537186
[TBL] [Abstract][Full Text] [Related]
76. Is there a role for tirapazamine in the treatment of cervical cancer?
Ghatage P; Sabagh H
Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1589-97. PubMed ID: 23033890
[TBL] [Abstract][Full Text] [Related]
77. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
Raymond E; ten Bokkel Huinink WW; Taïeb J; Beijnen JH; Faivre S; Wanders J; Ravic M; Fumoleau P; Armand JP; Schellens JH;
J Clin Oncol; 2002 Aug; 20(16):3508-21. PubMed ID: 12177112
[TBL] [Abstract][Full Text] [Related]
78. Paclitaxel as a radiation sensitizer in non-small cell lung cancer.
Choy H; Browne MJ
Semin Oncol; 1995 Jun; 22(3 Suppl 6):70-4. PubMed ID: 7597436
[TBL] [Abstract][Full Text] [Related]
79. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging.
Rosenthal DI; Nurenberg P; Becerra CR; Frenkel EP; Carbone DP; Lum BL; Miller R; Engel J; Young S; Miles D; Renschler MF
Clin Cancer Res; 1999 Apr; 5(4):739-45. PubMed ID: 10213207
[TBL] [Abstract][Full Text] [Related]
80. Neurotoxicity in a phase I trial of continuous infusion cisplatin with hyperfractionated radiotherapy for locally advanced head and neck cancer.
Clamon GH; Baatz L; Hoffman HT; Hussey DH; Glascock M; McCulloch TM; Graham SM
Head Neck; 1996; 18(3):236-41. PubMed ID: 8860764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]